Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer therapeutics - S*BIO

Drug Profile

Research programme: anticancer therapeutics - S*BIO

Alternative Names: EX2; EX44; EX45; EX58; SB1304; SB1354; SB2312; SB2602

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator S*BIO
  • Developer National University of Singapore; S*BIO
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Enzyme inhibitors; Fms-like tyrosine kinase 3 inhibitors; Histone deacetylase inhibitors; Janus kinase-2 inhibitors; MTOR protein inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Singapore (PO)
  • 29 Aug 2013 This programme is still active
  • 31 Mar 2010 Pacritinib, pracinostat, CT 1578, TG 02 and VS 5584 have been outlicensed prior to March 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top